FUSION SYSTEM
DEAD

Serial Number

90478027

Owner

Biomea Fusion, Inc.

Attorney

Philip R. Zender

Filing Date

Jan 20, 2021

Add to watchlist:

No watchlists yet
View on USPTO

FUSION SYSTEM Trademark

Serial Number: 90478027

FUSION SYSTEM is a trademark filed by Biomea Fusion, Inc. on January 20, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Biomea Fusion, Inc. (7 trademarks)

Redwood City, CA 94063

Entity Type: 03

Trademark Details

Filing Date

January 20, 2021

Registration Date

Not Registered

Published for Opposition

December 21, 2021

Goods & Services

Adjuvants for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Cellular function activating agents for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer and metabolic diseases; Chemotherapeutics; Cytostatics for pharmaceutical purposes; Diagnostic preparations for medical purposes; Medical preparations for the treatment of cancer and metabolic diseases; Medicinal infusions for treating cancer and metabolic diseases; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for cancer and metabolic diseases; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment and prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of cancer and metabolic diseases; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for cancer and metabolic diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer and metabolic diseases; Tumor suppressing agents

Providing a web site featuring medical information; Providing a website featuring information in the field of the diagnosis and treatment of cancer and metabolic diseases

Biotechnology research; Development of new technology for others in the field of cancer and metabolic diseases; Development of pharmaceutical preparations and medicines; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research services; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical research and scientific research information in the field of oncology via the Internet; Providing medical testing services and information in the field of cancer research and disease classification; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and metabolic diseases; Testing of pharmaceuticals

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 9, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 9, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 13, 2024 EXRA
SOU EXTENSION 5 GRANTED
Aug 13, 2024 EX5G
SOU EXTENSION 5 FILED
Aug 13, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Aug 13, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 9, 2024 EXRA
SOU EXTENSION 4 GRANTED
Feb 8, 2024 EX4G
SOU EXTENSION 4 FILED
Feb 8, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 8, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 15, 2023 EXRA
SOU EXTENSION 3 GRANTED
Aug 11, 2023 EX3G
SOU EXTENSION 3 FILED
Aug 11, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Aug 11, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 20, 2022 EXRA
SOU EXTENSION 2 GRANTED
Dec 16, 2022 EX2G
SOU EXTENSION 2 FILED
Dec 16, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 16, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 17, 2022 EXRA
SOU EXTENSION 1 GRANTED
Jun 15, 2022 EX1G
SOU EXTENSION 1 FILED
Jun 15, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 15, 2022 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 10, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 10, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 10, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 10, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 10, 2022 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 15, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 21, 2021 NPUB
PUBLISHED FOR OPPOSITION
Dec 21, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 1, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 15, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 12, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 12, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 12, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 15, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jul 15, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jul 15, 2021 CNRT
ASSIGNED TO EXAMINER
Jul 7, 2021 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 11, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 11, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 11, 2021 REAP
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 21, 2021 NWOS
NEW APPLICATION ENTERED
Jan 23, 2021 NWAP